Literature DB >> 25353284

Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.

Sarah M Voss1, Meghan P Riley, Parvez M Lokhandwala, Ming Wang, Zhaohai Yang.   

Abstract

Well-differentiated neuroendocrine tumors (WDNETs) of the pancreas are graded on the basis of mitotic count or Ki67 index. Mitotic count has a narrow cutoff; its assessment is time consuming and carries poor interobserver reproducibility. Phosphohistone H3 (PHH3) is a mitosis-specific marker whose value has been validated in several tumor types. We sought to assess the utility of PHH3 in histologic grading of pancreatic WDNETs. Sixty-three cases of surgically resected primary pancreatic WDNETs were retrieved, and immunohistochemical analysis for PHH3 and Ki67 was performed. Mitotic rate was independently assessed by 4 pathologists on hematoxylin and eosin (HE; in 50 high-power fields [HPFs], expressed as mitoses/10 HPF) and PHH3 stains (in 50 HPFs, one 10×, and one 20× hotspot). PHH3 and Ki67 labeling indices were determined on a single 20× hotspot and expressed as the percentage of positive cells to total cells. We found that mitotic counts by various methods significantly correlated with each other and also with PHH3 and Ki67 indices, with the best correlation seen within the 3 different PHH3 counts (in 50 HPFs, one 10× and one 20× hotspot). Moreover, mitotic count on PHH3 was less time consuming than that on HE (1.68 vs. 3.67 min for 50 HPFs, P<0.0001). Histologic grade determined by PHH3 significantly correlated with disease-specific and disease-free survivals, with the best cutoffs of ≥4 mitoses/10 HPF (2 mm), ≥7 mitoses/10× hotspot, ≥5 mitoses/20× hotspot (log rank test, P<0.0001), and ≥0.16% for PHH3 labeling index (log rank test, P<0.0006). Tumor grades based on PHH3 stain also showed significant correlation with patient survivals in multivariate Cox proportional hazards models (P<0.05). Histologic grades by mitotic counts on PHH3 demonstrated high concordance and κ agreement with grades determined by mitotic count on HE. PHH3 stain also showed improved interobserver agreement in both original mitotic count (intraclass correlation 0.98 vs. 0.79) and final grade assignment (Fleiss κ 0.69 vs. 0.46) as compared with HE. Thus, our data confirmed that histologic grading by PHH3 stain has practical and prognostic values and offers reduced time and improved interobserver reproducibility in mitotic rate assessment and grade assignment. Although larger series are needed for validation, mitotic rate can potentially be determined by counting 1 hotspot, which will greatly facilitate the assessment of histologic grade in pancreatic WDNETs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25353284     DOI: 10.1097/PAS.0000000000000341

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  19 in total

1.  Phosphohistone H3: implications for clinical practice and risk assessment in meningioma.

Authors:  Adriana Olar
Journal:  Neuro Oncol       Date:  2015-03-25       Impact factor: 12.300

2.  Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: A retrospective study of 136 patients.

Authors:  Kohei Ono; Eisuke Shiozawa; Nobuyuki Ohike; Tomonori Fujii; Hideki Shibata; Tetsuya Kitajima; Koichiro Fujimasa; Naoko Okamoto; Yukiko Kawaguchi; Tasuku Nagumo; Sakiko Tazawa; Mayumi Homma; Toshiko Yamochi-Onizuka; Tomoko Norose; Hitoshi Yoshida; Masahiko Murakami; Gensyu Tate; Masafumi Takimoto
Journal:  Oncol Lett       Date:  2017-12-08       Impact factor: 2.967

Review 3.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

4.  Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.

Authors:  Jessica Tracht; Kui Zhang; Deniz Peker
Journal:  J Histochem Cytochem       Date:  2017-05-22       Impact factor: 2.479

Review 5.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

6.  Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors.

Authors:  Annika Blank; Laura Wehweck; Ilaria Marinoni; Laura Amanda Boos; Frank Bergmann; Anja Maria Schmitt; Aurel Perren
Journal:  Virchows Arch       Date:  2015-09-17       Impact factor: 4.064

7.  The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.

Authors:  Sule Ozturk Sari; Orhun Cig Taskin; Gokcen Gundogdu; Gulcin Yegen; Semen Onder; Metin Keskin; Sezer Saglam; Yasemin Ozluk; Mine Gulluoglu; Ozgur Mete
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

8.  The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications.

Authors:  Marcela S Cavalcanti; Mithat Gönen; David S Klimstra
Journal:  Int J Endocr Oncol       Date:  2016-07-14

9.  Can PPH3 be helpful to assess the discordant grade in primary and metastatic enteropancreatic neuroendocrine tumors?

Authors:  Clotilde Dumars; Fanny Foubert; Yann Touchefeu; Nicolas Regenet; Hélène Senellart; Tamara Matysiak-Budnik; Marie-Françoise Heymann
Journal:  Endocrine       Date:  2016-04-05       Impact factor: 3.633

10.  Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.

Authors:  Vincenzo Villani; Krishnan K Mahadevan; Matteo Ligorio; Carlos Fernández-Del Castillo; David T Ting; Francesco Sabbatino; Irene Zhang; Mark Vangel; Soldano Ferrone; Andrew L Warshaw; Keith D Lillemoe; Jennifer Wargo; Vikram Deshpande; Cristina R Ferrone
Journal:  Ann Surg Oncol       Date:  2016-03-28       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.